INBP (Integrated Biopharma) Days Payable : 22.21 (As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Days Payable?

Integrated Biopharma's average Accounts Payable for the three months ended in Dec. 2024 was $2.79 Mil. Integrated Biopharma's Cost of Goods Sold for the three months ended in Dec. 2024 was $11.44 Mil. Hence, Integrated Biopharma's Days Payable for the three months ended in Dec. 2024 was 22.21.

The historical rank and industry rank for Integrated Biopharma's Days Payable or its related term are showing as below:

INBP' s Days Payable Range Over the Past 10 Years
Min: 18.77 Med: 33.04 Max: 58.45
Current: 23.36

During the past 13 years, Integrated Biopharma's highest Days Payable was 58.45. The lowest was 18.77. And the median was 33.04.

INBP's Days Payable is ranked worse than
81.16% of 1821 companies
in the Consumer Packaged Goods industry
Industry Median: 45.69 vs INBP: 23.36

Integrated Biopharma's Days Payable declined from Dec. 2023 (28.40) to Dec. 2024 (22.21). It may suggest that Integrated Biopharma accelerated paying its suppliers.

Integrated Biopharma Days Payable Historical Data

The historical data trend for Integrated Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Days Payable Chart

Integrated Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Payable

Get a 7-Day Free Trial

32.55

26.50

24.62

21.44

18.77

Integrated Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															28.40	26.76	24.61	19.65	22.21

Competitive Comparison of Integrated Biopharma's Days Payable

For the Packaged Foods subindustry, Integrated Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Biopharma's Days Payable Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Days Payable falls into.

Save Embed

;

Save Embed

;

Integrated Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Integrated Biopharma's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as

	Days Payable (A: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2023 )	+	Accounts Payable (A: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2024 )	*	Days in Period
=	( (2.266	+	2.51)	/	2 )	/	46.433	*	365
=	2.388					/	46.433	*	365
=	18.77

Integrated Biopharma's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (2.763	+	2.808)	/	2 )	/	11.443	*	365 / 4
=	2.7855					/	11.443	*	365 / 4
=	22.21

Integrated Biopharma Days Payable Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

https://ir.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from Contract Manufacturing segment which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431